Colocalization of Somatostatin Receptors and Epidermal Growth Factor Receptors in Breast Cancer Cells

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2006 Mar 8

PMID 16519802

Citations 10

Authors

Heather L Watt

Ujendra Kumar

Affiliations

Soon will be listed here.

Abstract

Background: Somatostatin receptor (SSTR) expression is positively correlated with tumor size and inversely correlated with epidermal growth factor receptor (ErbB) levels and tumor differentiation. In the present study, we compared SSTR1-5 and ErbB1-4 mRNA and protein expression in two breast cancer cell lines: MCF-7 (ER+) and MDA-MB-231 (ERalpha-).

Results: All five SSTRs and four ErbBs were variably expressed as both cell surface and cytoplasmic proteins. In both cell lines, SSTR4 and SSTR1 were highly expressed, followed by SSTR2 and SSTR5 with SSTR3 being the least expressed subtype, at the protein level. ErbBs were variably expressed with ErbB1 as the predominant subtype in both cell lines. ErbB1 is followed by ErbB3, ErbB2 and ErbB4 in MCF-7 at both the protein and mRNA levels. In MDA-MB-231 cells, ErbB1 is followed by ErbB2, ErbB4 and ErbB3. Our results indicate significant correlations at the level of mRNA and protein expression in a cell and receptor-specific manner. Using indirect immunofluorescence, we found that, in MCF-7 cells, SSTR5 was the most prominent subtype coexpressed with ErbBs followed by SSTR3, SSTR4, SSTR1 and SSTR2, respectively. In MDA-MB-231 cells, SSTR1 colocalized strongly with ErbBs followed by SSTR5, SSTR4, SSTR3 and SSTR2. ErbBs displayed higher levels of colocalization amongst themselves in MCF-7 cells than in MDA-MB-231 cells.

Conclusion: These findings may explain the poor response to endocrine therapy in ER-cancer. Differential distribution of SSTR subtypes with ErbBs in breast cancer cells in a receptor-specific manner may be considered as a novel diagnosis for breast tumors.

Citing Articles

Role of Endorphins in Breast Cancer Pathogenesis and Recovery.

Nguyen D Adv Neurobiol. 2024; 35:87-106.

PMID: 38874719 DOI: 10.1007/978-3-031-45493-6_5.

Somatostatin and Somatostatin Receptors in Tumour Biology.

Kumar U Int J Mol Sci. 2024; 25(1).

PMID: 38203605 PMC: 10779198. DOI: 10.3390/ijms25010436.

Expression and selective activation of somatostatin receptor subtypes induces cell cycle arrest in cancer cells.

Zou Y, Tan H, Zhao Y, Zhou Y, Cao L Oncol Lett. 2019; 17(2):1723-1731.

PMID: 30675231 PMC: 6341781. DOI: 10.3892/ol.2018.9773.

Ablation of neuropsin-neuregulin 1 signaling imbalances ErbB4 inhibitory networks and disrupts hippocampal gamma oscillation.

Kawata M, Morikawa S, Shiosaka S, Tamura H Transl Psychiatry. 2017; 7(3):e1052.

PMID: 28267150 PMC: 5416666. DOI: 10.1038/tp.2017.20.

Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo.

Liu T, Jia T, Yuan X, Liu C, Sun J, Ni Z Int J Nanomedicine. 2016; 11:2235-50.

PMID: 27284243 PMC: 4883818. DOI: 10.2147/IJN.S100404.

References

Nelson J, Cremin M, Murphy R . Synthesis of somatostatin by breast cancer cells and their inhibition by exogenous somatostatin and sandostatin. Br J Cancer. 1989; 59(5):739-42. PMC: 2247230. DOI: 10.1038/bjc.1989.154. View

deFazio A, Chiew Y, Donoghue C, Lee C, Sutherland R . Effect of sodium butyrate on estrogen receptor and epidermal growth factor receptor gene expression in human breast cancer cell lines. J Biol Chem. 1992; 267(25):18008-12. View

Buscail L, Vernejoul F, Faure P, Torrisani J, Susini C . [Regulation of cell proliferation by somatostatin]. Ann Endocrinol (Paris). 2002; 63(2 Pt 3):2S13-8. View

Sweeney C, Carraway 3rd K . Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage. Oncogene. 2000; 19(49):5568-73. DOI: 10.1038/sj.onc.1203913. View

Ciocca D, Puy L, Fasoli L, Tello O, Aznar J, Gago F . Corticotropin-releasing hormone, luteinizing hormone-releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients. Breast Cancer Res Treat. 1990; 15(3):175-84. DOI: 10.1007/BF01806354. View

Mueller H, Loop P, Liu R, Wosikowski K, Kueng W, Eppenberger U . Differential signal transduction of epidermal-growth-factor receptors in hormone-dependent and hormone-independent human breast cancer cells. Eur J Biochem. 1994; 221(2):631-7. DOI: 10.1111/j.1432-1033.1994.tb18775.x. View

Watters J, Campbell J, Cunningham M, KREBS E, Dorsa D . Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. Endocrinology. 1997; 138(9):4030-3. DOI: 10.1210/endo.138.9.5489. View

Kumar U, Laird D, Srikant C, Escher E, Patel Y . Expression of the five somatostatin receptor (SSTR1-5) subtypes in rat pituitary somatotrophes: quantitative analysis by double-layer immunofluorescence confocal microscopy. Endocrinology. 1997; 138(10):4473-6. DOI: 10.1210/endo.138.10.5566. View

Reubi J, Schaer J, Waser B, Mengod G . Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res. 1994; 54(13):3455-9. View

10.

Hukovic N, Panetta R, Kumar U, Patel Y . Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. Endocrinology. 1996; 137(9):4046-9. DOI: 10.1210/endo.137.9.8756582. View

11.

Cattaneo M, Taylor J, Culler M, Nisoli E, Vicentini L . Selective stimulation of somatostatin receptor subtypes: differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells. FEBS Lett. 2000; 481(3):271-6. DOI: 10.1016/s0014-5793(00)02012-3. View

12.

Tzahar E, Pinkas-Kramarski R, Moyer J, Klapper L, Alroy I, Levkowitz G . Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J. 1997; 16(16):4938-50. PMC: 1170129. DOI: 10.1093/emboj/16.16.4938. View

13.

Olayioye M, Neve R, Lane H, Hynes N . The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000; 19(13):3159-67. PMC: 313958. DOI: 10.1093/emboj/19.13.3159. View

14.

Kumar U, Grigorakis S, Watt H, Sasi R, Snell L, Watson P . Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1--5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res Treat. 2005; 92(2):175-86. DOI: 10.1007/s10549-005-2414-0. View

15.

Abd El-Rehim D, Pinder S, Paish C, Bell J, Rampaul R, Blamey R . Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer. 2004; 91(8):1532-42. PMC: 2410019. DOI: 10.1038/sj.bjc.6602184. View

16.

Lacroix M, Leclercq G . Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat. 2004; 83(3):249-89. DOI: 10.1023/B:BREA.0000014042.54925.cc. View

17.

Weber C, Merriam L, Koschitzky T, Karp F, Benson M, Forde K . Inhibition of growth of human breast carcinomas in vivo by somatostatin analog SMS 201-995: treatment of nude mouse xenografts. Surgery. 1989; 106(2):416-22. View

18.

Pierce K, Premont R, Lefkowitz R . Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002; 3(9):639-50. DOI: 10.1038/nrm908. View

19.

Ramirez J, Grant M, Norman M, Wang X, Moldovan S, de Mayo F . Deficiency of somatostatin (SST) receptor type 5 (SSTR5) is associated with sexually dimorphic changes in the expression of SST and SST receptors in brain and pancreas. Mol Cell Endocrinol. 2004; 221(1-2):105-19. DOI: 10.1016/j.mce.2004.02.001. View

20.

Grant M, Patel R, Kumar U . The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors. J Biol Chem. 2004; 279(37):38636-43. DOI: 10.1074/jbc.M406276200. View